Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25220506 | 0.86 | CYP3A4 (0.50) | CYP2C9CYP3A4CYP2C19CYP1A2THPO | |
| SCHEMBL30426279 | 0.86 | CYP3A4 (0.50) | CYP2C9CYP3A4CYP2C19CYP1A2THPO | |
| SCHEMBL4973133 | 0.83 | CA12 (0.56) | CYP2C9CYP1A2CA12CA1CA2 | |
| SCHEMBL10055174 | 0.82 | CYP2C19 (0.47) | CYP2C9CYP3A4CYP2C19CYP1A2THPO | |
| SCHEMBL46622 | 0.81 | ASIC3 (0.48) | CYP2C9CYP2C19CYP1A2CA12CA1 | |
| SCHEMBL10412856 | 0.80 | CA12 (0.52) | CYP2C9CYP1A2CA12CA1CA2 | |
| SCHEMBL1927619 | 0.80 | SLC7A11 (0.55) | CYP2C9CYP1A2CA12CA1CA2 | |
| SCHEMBL31244037 | 0.79 | CYP2C19 (0.70) | CYP2C9CYP3A4CYP2C19CYP1A2THPO | |
| SCHEMBL16719361 | 0.79 | GRM5 (0.55) | CYP2C9CYP3A4CYP2C19CYP1A2BLM | |
| SCHEMBL13780436 | 0.77 | CA12 (0.48) | CYP2C9CYP1A2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214691-B1 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY | UNIV INDIANA RES & TECH CORP (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8980830-B2 | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20110098217-A1 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2214691-A1 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY | Indiana University Research and Technology Corporation (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009058734-A1 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098217-A1 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY | GLP1R, GIPR, GCGR | CYP2C9 4695/4885CYP3A4 4718/4885CYP2C19 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.